CooperCompanies stock holds steady after Q3 beats estimates

Earnings and valuation

CooperCompanies (US21664P1039) closed at $76.17 on August 14, 2026, with MarketBeat showing a market capitalization of $14.86 billion and a 52-week range of $58.89 to $89.83. The same page puts the stock at $76.17 after a June 4, 2026 earnings report that showed $1.21 in quarterly EPS, above the $1.10 consensus by $0.11.

That comparison matters because the latest reported quarter also showed revenue up 7.9% year over year, which gives the valuation context more weight than the flat day-to-day quote. The stock's year-to-date move is still negative from the $81.96 start of 2026, a reminder that the June beat has not fully reset investor expectations.

Analyst backdrop

Consensus pricing remains modestly above the latest close, with a $81.64 average target and a $103.00 high target in the current market snapshot. That implies 7.19% upside from the August 14 close, while the median view still leaves room for the shares to recover without needing a rerating to the upper end of the range.

The broader setup is straightforward: the stock has been trading inside a relatively wide band, but the most recent earnings line was constructive and the analyst stack still leans to a price level above the last close. For investors, the focus is now on whether the next reported quarter can extend the 7.9% revenue growth and keep EPS ahead of estimates.

CooperSurgical and CooperVision

CooperCompanies' two main businesses, CooperVision and CooperSurgical, frame the investment case differently because one is tied to contact lenses and the other to women's health and fertility products. That mix matters when quarterly revenue growth and margin trends are read against the company's current $14.86 billion equity value.

CooperVision remains the larger consumer-facing growth engine, while CooperSurgical adds exposure to procedure-driven demand and a different reimbursement profile. The pair gives the company a broader operating base than a single-line medical device peer, which helps explain why the stock can hold a premium multiple even after an earnings beat is already in the price.

Stock level

CooperCompanies stock traded at $76.17 on August 14, 2026, and the snapshot also showed extended trading at $76.78. The shares sit below the 2026 starting level of $81.96, but above the low end of the $58.89 to $89.83 range.

Company

Company: CooperCompanies, Inc.
ISIN: US21664P1039
Ticker: COO
Exchange: Nasdaq
Price (as of August 14, 2026, 4:00 p.m. ET): $76.17 USD
Market cap: $14.86 billion (as of August 14, 2026)
Sector / Industry: Health Care / Health Care Equipment
Index membership: S&P 500